conv.

All stories
AIQuiet 5d · day 5

Altis Labs raises $25M Series A for AI cancer trial analysis

Toronto startup's AI model detects treatment effects months earlier than traditional methods in oncology trials.

newest coverage 5d agosummary written 4d ago2 pieces Newswires

What to know

  • Altis Labs secured $25M Series A from OrbiMed and Qiming Venture Partners USA to scale its IPRO AI model for oncology clinical trials.
  • IPRO detected treatment effects 11–26 months faster than traditional methods in a Johnson & Johnson lung cancer trial analyzing 10,000 scans.
  • The company plans to expand its model to more cancer types and establish AI endpoints as a new standard in drug development trials.

“Drug developers rely on early endpoints for trial design and portfolio decisions, so they might prematurely discontinue promising treatments or move forward with flawed therapies based on traditional endpoint analysis.”

Altis Labs · BetaKit ↗

Altis Labs AI healthcare startupFelix Baldauf-Lenschen Altis Labs co-founder and CEOOrbiMed Series A co-lead investorQiming Venture Partners USA Series A co-lead investor

Altis Labs raises $25M Series A for AI cancer trial analysis
betakit.com

How it unfolded 1 development · click the chart to see its coverage articles

Peak 2 pieces in two hours at Sep 20, 11 PM; 2 pieces over 6 days (2 articles) Sep 20, 11 PM — 2 pieces · 2 articles — Newswires 2Sep 21, 1 AM — quietSep 21, 3 AM — quietSep 21, 5 AM — quietSep 21, 7 AM — quietSep 21, 9 AM — quietSep 21, 11 AM — quietSep 21, 1 PM — quietSep 21, 3 PM — quietSep 21, 5 PM — quietSep 21, 7 PM — quietSep 21, 9 PM — quietSep 21, 11 PM — quietSep 22, 1 AM — quietSep 22, 3 AM — quietSep 22, 5 AM — quietSep 22, 7 AM — quietSep 22, 9 AM — quietSep 22, 11 AM — quietSep 22, 1 PM — quietSep 22, 3 PM — quietSep 22, 5 PM — quietSep 22, 7 PM — quietSep 22, 9 PM — quietSep 22, 11 PM — quietSep 23, 1 AM — quietSep 23, 3 AM — quietSep 23, 5 AM — quietSep 23, 7 AM — quietSep 23, 9 AM — quietSep 23, 11 AM — quietSep 23, 1 PM — quietSep 23, 3 PM — quietSep 23, 5 PM — quietSep 23, 7 PM — quietSep 23, 9 PM — quietSep 23, 11 PM — quietSep 24, 1 AM — quietSep 24, 3 AM — quietSep 24, 5 AM — quietSep 24, 7 AM — quietSep 24, 9 AM — quietSep 24, 11 AM — quietSep 24, 1 PM — quietSep 24, 3 PM — quietSep 24, 5 PM — quietSep 24, 7 PM — quietSep 24, 9 PM — quietSep 24, 11 PM — quietYesterday, 1 AM — quietYesterday, 3 AM — quietYesterday, 5 AM — quietYesterday, 7 AM — quietYesterday, 9 AM — quietYesterday, 11 AM — quietYesterday, 1 PM — quietYesterday, 3 PM — quietYesterday, 5 PM — quietYesterday, 7 PM — quietYesterday, 9 PM — quietYesterday, 11 PM — quietToday, 1 AM — quietToday, 3 AM — quietToday, 5 AM — quietToday, 7 AM — quietToday, 9 AM — quiet 1
Sep 21Sep 22Sep 23Sep 24yesterdaynow · 11:46 AM ET
  1. background

    IPRO model shows significant speed advantage in lung cancer trial — Altis claims its IPRO model can automatically generate survival predictions from radiology scans, enabling drug developers to detect treatment effects earlier and more reliably than traditional endpoint methods in oncology trials.

  2. 1

    Altis Labs closes $25M Series A funding round

    Toronto-based healthtech startup Altis Labs announced completion of a $25 million USD ($35 million CAD) Series A round co-led by biotech investor OrbiMed and Qiming Venture Partners USA. The funding will support expansion of the company's AI-powered prognosis platform for clinical trials.

    “Altis Labs has closed a $25-million USD ($35-million CAD) Series A round to expand its AI-powered prognosis platform for clinical trials.”
    — BetaKit · source
    1. 1 outlet Altis Labs raises $25 million USD Series A to expand AI for cancer trials

      first by BetaKit, 5d ago